Rock Capital Group. (11/5/24). "Press Release: Praimera Biotech AG Rents 600 m² of Lab Office Space at Skygate in Hallbergmoos near Munich". Munich-Hallbergmoos.

	Organisation	Skygate München Lab Building
	Group	Rock Capital (Group)
	Organisation 2	Praimera Biotech AG
	Product	business park management / science park management
	Product 2	AI-based drug discovery / AI-based drug development
	Person	Biebl, Maximilian (Praimera Biotech 202411 CEO + CSO)
	Person 2	Wißmeier, Andreas (Rock Capital 202406 Managing Director)

With the latest letting success to Praimera Biotech AG, the Rock Capital Group has let 2,700 square metres of ready-to-use lab offices in recent weeks. Further lettings are to follow.

The Rock Capital Group is continuing its successful course at the SKYGATE biotech and life science hub in the Munich Airport Business Park (MABP) in Hallbergmoos near Munich. With Praimera Biotech AG, another forward-looking company has been acquired as a tenant. Praimera Biotech is moving into around 600 square metres on the ground floor of the SKYGATE hotel, office and biotech building complex.

"With our concept of S1 and S2 laboratory space available at short notice, we have our finger on the pulse of the times. There is a serious shortage of this specialised space in the greater Munich area. SKYGATE closes the gap and offers companies that need laboratory space or lab offices the ideal infrastructure for their research activities," explains Andreas Wißmeier, Managing Director of Rock Capital Group. Just a few weeks ago, the Rock Capital Group leased 1,500 square metres of ready-to-use lab offices to Samsung SDI Europe and 600 square metres to Sungrow. Like Praimera Biotech, both companies now want to continue their existing research activities in SKYGATE in the ultra-modern, professional environment that SKYGATE offers.

More than just a laboratory: ideal conditions for employees and research

Praimera Biotech AG is dedicated to the development of pioneering technologies and products in the biopharmaceutical sector. The company focusses in particular on the research and development of novel drugs. "The New Work office and laboratory space in combination with the unique environment of SKYGATE offer us ideal starting conditions for our research and development activities. The good transport links, proximity to Munich Airport and the hotel and catering infrastructure provide our employees with the best conditions. With our work, we want to contribute to further establishing and developing the location as an innovation hub," emphasises Dr Maximilian Biebl, CEO and CSO of Praimera Biotech AG.

SKYGATE scores points not only with its highly specialised laboratory space. The complex offers a holistic concept for modern working environments. Flexible open-space office areas and socialising spots promote creative exchange, while fully equipped meeting rooms with state-of-the-art conference technology enable professional collaboration. An in-house catering service takes care of your physical well-being. An integrated hotel from Radisson Individuals with 212 rooms offers hospitality directly on site. The proximity to the unique new and largest surf park in Europe, O2 SURFTOWN MUC, rounds off the overall package and emphasises the claim to optimally combine work and leisure.

"With SKYGATE, we have created a place that combines science, innovation and quality of life," says Wißmeier, adding: "Our aim is to establish a leading life science and biotech centre in the north of Munich. The arrival of Praimera Biotech AG is another important step in this direction."

About Praimera Biotech AG

Praimera Biotech AG is an innovative start-up in the life sciences sector. Praimera combines scientific excellence with many years of entrepreneurial experience in the biopharmaceutical and pharmaceutical industry. Its business activities focus on the development of a technology platform for next-generation therapeutic antibodies with completely new functional properties. To this end, the latest findings from protein science and biopharmaceuticals are combined with the enormous potential of artificial intelligence, computer-aided molecular dynamics simulations and machine learning. By utilising new technologies and tools, the development times for innovative antibodies can be shortened and urgently needed new therapeutic options for serious chronic and life-threatening diseases can be created. Praimera Biotech AG is supported by a large network of private investors.

Record changed: 2024-11-25